Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | GRM4 | Q14833 | 15/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | ITK | Q08881 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29498332 | 1.00 | PDPK1 (0.52) | PDPK1GAAKDM4ECYP3A4GRM4 | |
| Hydrochloric Acid SCHEMBL30278764 | 0.98 | PDPK1 (0.50) | PDPK1GAAKDM4ECYP3A4GRM4 | |
| Hydrochloric Acid SCHEMBL29647922 | 0.98 | PDPK1 (0.50) | PDPK1GAAKDM4ECYP3A4GRM4 | |
| Urea SCHEMBL28025849 | 0.91 | ITK (0.44) | PDPK1GAAKDM4ECYP3A4GRM4 | |
| SCHEMBL2490624 | 0.88 | ITK (0.45) | PDPK1GAAKDM4ECYP3A4GRM4 | |
| SCHEMBL27085309 | 0.82 | GRM4 (0.38) | PDPK1GAAKDM4ECYP3A4GRM4 | |
| Hydrochloric Acid SCHEMBL29207569 | 0.81 | GRM4 (0.37) | PDPK1GAAKDM4ECYP3A4GRM4 | |
| SCHEMBL23495733 | 0.76 | NUDT1 (0.43) | PDPK1GAAKDM4ECYP3A4GRM4 | |
| SCHEMBL569822 | 0.75 | GRM4 (0.50) | GRM4ITK | |
| SCHEMBL516990 | 0.75 | GRM4 (0.50) | GRM4ITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 425 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250143992-A1 | VAT PLUS OXIDATIVE COLORS | WELLA GERMANY GMBH (DE) | 2025-05-08 | — | — | US | claimed |
| EP-3873407-B1 | TWO-COMPONENT SYSTEM FOR ARTIFICIAL HAIR DYEING | HENKEL AG & CO KGAA (DE) | 2025-04-09 | — | — | EP | claimed |
| EP-4475959-A1 | HAIR COLORING USING OXIDATIVE DYE PRECURSORS COMPRISING PYRAZOLE PRIMARIES AND COUPLERS, IN COMBINATION WITH SOLUBILIZED VAT DYES, FOR IMPROVING COLOR WASH FASTNESS | Wella Germany GmbH (DE) | 2024-12-18 | — | — | EP | claimed |
| WO-2023152322-A1 | HAIR COLORING USING OXIDATIVE DYE PRECURSORS COMPRISING PYRAZOLE PRIMARIES AND COUPLERS, IN COMBINATION WITH SOLUBILIZED VAT DYES, FOR IMPROVING COLOR WASH FASTNESS | WELLA GERMANY GMBH (DE) | 2023-08-17 | — | — | WO | claimed |
| EP-3515913-B1 | AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES | NOVARTIS AG (CH) | 2022-05-11 | — | — | EP | claimed |
| CN-109912606-B | Synthesis method of pyrimido indazole compound | 新乡医学院 | 2021-05-04 | — | — | CN | claimed |
| EP-3638200-A1 | PROCESS FOR DYEING KERATIN MATERIALS USING AT LEAST ONE BLUE, PURPLE OR GREEN DYE AND AT LEAST ONE DISULFIDE, THIOL OR PROTECTED THIOL FLUORESCENT DYE | L'Oreal (FR) | 2020-04-22 | — | — | EP | claimed |
| CN-111032008-A | Method for dyeing keratin materials using at least one blue, violet or green dye and at least one disulfide, thiol or protected thiol fluorescent dye | 莱雅公司 | 2020-04-17 | — | — | CN | claimed |
| US-10472420-B2 | Immune response modifier conjugates | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2019-11-12 | — | — | US | claimed |
| EP-2464424-B1 | DYE COMPOSITION COMPRISING A HETEROCYCLIC OXIDATION BASE AND AN INDOLE COUPLER | OREAL (FR) | 2019-09-25 | — | — | EP | claimed |
| WO-2007079202-A2 | TREATMENT FOR ACUTE LYMHOBLASTIC LEUKEMIA | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2007-07-12 | — | — | WO | claimed |
| EP-1804583-A2 | ADJUVANT FOR DNA VACCINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-07-11 | — | — | EP | claimed |
| EP-1799256-A2 | METHOD OF ELICITING AN IMMUNE RESPONSE AGAINST HIV | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-06-27 | — | — | EP | claimed |
| WO-2006130399-A2 | THERAPEUTIC COMBINATIONS AND METHODS INCLUDING IRM COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-12-07 | — | — | WO | claimed |
| WO-2006063152-A2 | IMMUNOSTIMULATORY COMBINATIONS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-06-15 | — | — | WO | claimed |
| WO-2006042254-A2 | ADJUVANT FOR DNA VACCINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-04-20 | — | — | WO | claimed |
| WO-2006026394-A2 | METHOD OF ELICITING AN IMMUNE RESPONSE AGAINST HIV | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-03-09 | — | — | WO | claimed |
| US-20060045885-A1 | Method of eliciting an immune response against HIV | GOVERNMENT OF THE UNITED STRATS OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE | 2006-03-02 | — | — | US | claimed |
| US-20050267145-A1 | Treatment for lung cancer | COLEY PHARMACEUTICAL GROUP, INC. | 2005-12-01 | — | — | US | claimed |
| US-20050226878-A1 | Therapeutic combinations and methods including IRM compounds | 3M INNOVATIVE PROPERTIES COMPANY | 2005-10-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250143992-A1 | VAT PLUS OXIDATIVE COLORS | VAT1, POR, GSR | PDPK1 2671/4885GAA 2569/4885KDM4E 464/4885 |
| US-10472420-B2 | Immune response modifier conjugates | IFNG, CD74, MYD88 | PDPK1 4283/4885GAA 3355/4885KDM4E 2631/4885 |
| US-20060045885-A1 | Method of eliciting an immune response against HIV | CD69, IRF3, CD4 | PDPK1 3979/4885GAA 4180/4885KDM4E 4684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.